BriaCell Therapeutics Corporation
0.2375 (3.48%)
Upgrade to Real-Time
Regular Market
Volume 88,621
Bid Price 7.05
Ask Price 7.10
News -
Day High 7.25


52 Week Range


Day Low 6.83
Company Name Stock Ticker Symbol Market Type
BriaCell Therapeutics Corporation BCTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.2375 3.48% 7.0675 14:34:39
Open Price Low Price High Price Close Price Prev Close
6.83 6.83 7.25 6.83
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
631 88,621 $ 7.04 $ 624,324 - 4.06 - 12.09
Last Trade Time Type Quantity Stock Price Currency
14:40:46 1 $ 7.075 USD


Draw Mode:

BriaCell Therapeutics Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 109.67M 15.52M 13.38M $ - $ - -3.38 -4.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 52.53k -

more financials information »

BriaCell Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BCTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week7.537.826.7457.25179,061-0.4625-6.14%
1 Month5.437.825.306.89271,0081.6430.16%
3 Months5.957.824.236.01214,4111.1218.78%
6 Months6.568.374.236.38319,8370.50757.74%
1 Year6.2312.094.067.40461,3960.837513.44%
3 Years4.2412.472.81496.651,383,8142.8366.69%
5 Years4.2412.472.81496.651,383,8142.8366.69%

BriaCell Therapeutics Description

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. BriaCell is conducting a Phase II clinical trial of Bria-IMT in metastatic advanced breast cancer (Fast Track designation from FDA). BriaCell is developing Bria-OTS, a personalized off the shelf immunotherapy for cancer based on matching the patient's HLA type. Enhanced cellular immunotherapies with enhanced potency are under development.